Copyright
©The Author(s) 2024.
World J Gastroenterol. Apr 7, 2024; 30(13): 1911-1925
Published online Apr 7, 2024. doi: 10.3748/wjg.v30.i13.1911
Published online Apr 7, 2024. doi: 10.3748/wjg.v30.i13.1911
Figure 3 Differential expression metabolites in serum metabolomics of pAAV-HBV1.
2 replication mice treated with Liuweiwuling Tablet. A: Volcanogram of differentially expressed metabolites (DEMs); B: Heat map of DEMs between High-dose Liuweiwuling Tablet group (HG)/control group (CG); C: Kyoto Encyclopedia of Genes and Genomes pathway enrichment for the DEMs between HG/CG; D: Receiver operating characteristic curve validation of the DEMs between HG/CG; E: Heat map of eight key DEMs between HG/CG; F: Potential apoptosis-related metabolic pathways of Liuweiwuling Tablet against hepatitis B virus. LWWL: Liuweiwuling Tablet; HG: High-dose LWWL group; LG: Low-dose LWWL group; CG: Control group; TG: Tenofovir disoproxil fumarate group.
- Citation: Ge FL, Yang Y, Si LL, Li YH, Cao MZ, Wang J, Bai ZF, Ren ZG, Xiao XH, Liu Y. Inhibition of hepatitis B virus via selective apoptosis modulation by Chinese patent medicine Liuweiwuling Tablet. World J Gastroenterol 2024; 30(13): 1911-1925
- URL: https://www.wjgnet.com/1007-9327/full/v30/i13/1911.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i13.1911